Patents Assigned to Self-screen B.V.
  • Patent number: 11932909
    Abstract: The invention relates to method for detecting HPV-induced high-grade precancerous lesions, HPV-induced invasive cancers and nonHPV-induced gynaecological and anogenital cancers, said method comprising detection of a methylation classifier consisting of the genes LHX8, ASCL1 and ST6GALNAC5 and their regulatory sequence in a cell whereby such hypermethylation indicates the presence of HPV-induced precursor lesions with invasive potential, HPV-induced invasive cancers and nonHPV-induced gynaecological and anogenital cancers. The invention further comprises the use of the methylation classifier consisting of genes LHX8, ASCL1 and ST6GALNAC5 and their regulatory sequence in such a method and a test kit for the detection of LHX8. ASCL1 and/or ST6GALNAC5 methylation.
    Type: Grant
    Filed: March 9, 2018
    Date of Patent: March 19, 2024
    Assignee: SELF-SCREEN B.V.
    Inventors: Christophorus Joannes Lambertus Maria Meijer, Renske Daniëla Maria Steenbergen, Petrus Josephus Ferdinandus Snijders, Daniëlle Anne Marie Heideman
  • Patent number: 9890432
    Abstract: The invention relates to method for detecting HPV-induced high-grade precancerous lesions and HPV-induced invasive cancers, said method comprising detection of hypermethylation in the PRDM14 and/or FAM19A4 gene in a cell whereby such hypermethylation indicates the presence of HPV-induced precursor lesions with invasive potential and HPV-induced invasive cancers. The invention further comprises the use of the PRDM14 and/or FAM19A4 gene in such a method and a testkit for the detection of PRDM14 and/or FAM19A4 methylation.
    Type: Grant
    Filed: October 14, 2013
    Date of Patent: February 13, 2018
    Assignee: SELF-SCREEN B.V.
    Inventors: Christophorus Joannes Lambertus Maria Meijer, Petrus Josephus Ferdinandus Snijders, Renske Daniëla Maria Steenbergen
  • Patent number: 9435001
    Abstract: The invention describes a consensus PCR based method (i.e. HRE7-PCR) for the simultaneous detection of 14 Human Papilloma Virus types (i.e. HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) that are classified as (probably) high-risk, relating to the causation of cervical cancer) and a candidate hrHPV type (i.e. HPV 67) using sets of 6 overlapping forward primers and 9 overlapping backward primers that together amplify a fragment of about (215) to (245) base pairs of the E7 open reading frame of these hrHPV types. For the detection of reaction products an EIA format can be used with the aid of a cocktail of type-specific oligoprobes as exemplified herein. Furthermore, we have developed a method for an efficient typing of these (15) HPVs that is compatible with the method for detection. This RLB typing system involves hybridization of PCR products with immobilized type-specific oligoprobes.
    Type: Grant
    Filed: November 1, 2007
    Date of Patent: September 6, 2016
    Assignee: SELF-SCREEN B.V.
    Inventors: Christophorus Joannes Lambertus Maria Meijer, Petrus Josephus Ferdinandus Snijders
  • Publication number: 20150225796
    Abstract: The inventors now have developed a (molecular) diagnostic assay based on detection of alterations in markers MAL and hsa-mi R124, in particular promoter hypermethylation, to identify human papillomavirus (HPV)-induced high-grade precancerous lesions such as premalignant cervical lesions of invasive cervical cancer, within cell material obtained via self-sampling. In particular, the present invention relates to the use of the MAL gene (including its promoter) and the hsa-mi R124 gene as marker for HPV-induced high-grade premalignant lesions, allowing early detection and a better treatment option for the individual patient.
    Type: Application
    Filed: September 13, 2012
    Publication date: August 13, 2015
    Applicant: Self-screen B.V.
    Inventors: Petrus Josephus Ferdinandus Snijders, Renske Daniëla Maria Steenbergen, Daniëlle Anne Marie Heideman, Christophorus Joannes Lambertus Maria Meijer